Actithera Strengthens Clinical Operations Leadership for Radioligand Therapy Programs

According to a recent LinkedIn post from Actithera, the company has brought on Juergen Fleck as Head of Clinical Operations. The post highlights his background in radioligand therapy and experience leading complex clinical programs in oncology-focused biotech settings.

The post suggests Actithera is strengthening its operational leadership as it advances radioligand therapy programs toward later-stage development. For investors, this could indicate a growing clinical pipeline and a push toward execution discipline, which may influence timelines, trial quality, and the company’s overall attractiveness as a platform in the radioligand oncology space.